Denver Myeloma Roundtable
Join us for the Denver Myeloma Round Table at the Sheraton Denver Downtown Hotel, located at 1550 Court Place, Denver, CO 80202, on September 12th from 9:00 am-2:30 pm MST to hear from top myeloma researchers. The day includes informative and engaging presentations about the latest in myeloma as well as breakout sessions for both newly diagnosed and relapsed/refractory patients. The event will feature two sessions that include extensive Q&A. Registration and breakfast open at 8:00 am.
Meeting Details
- Meeting date: Saturday, September 12th, 2026
- Registration opens, and breakfast starts at 8:00 am; the meeting begins at 9:00 am
- Location: Sheraton Denver Downtown Hotel. 1550 Court Place, Denver, CO 80202
- Event Rooms: Main room: Majestic Ballroom. Meals and breakout sessions: Vail Vallroom
- Included: parking, breakfast, lunch, and refreshments
- The meeting will be recorded and available to watch at a later time
- Nearest airport: Denver International Airport (DEN)
Register to watch the recording
If you are unable to attend the meeting in person, we invite you to register to receive access to the recording.
Please note that this event will not be livestreamed. A recording of the program will be available approximately 1 week after the live event, and all registered individuals will receive an email with viewing instructions once it is ready.
Make it a weekend
If you are traveling to the meeting and would like to make a weekend of it while you are in Denver, here are some suggestions:
- Top three hotels: Sheraton Denver Downtown Hotel (special rate link coming soon), Sonesta Denver Downtown, and The Brown Palace
- Top three restaurants: Maggiano's Little Italy, Earl's Kitchen, and The Fire.
- Top three activities: Denver Botanic Gardens, Denver downtown, and Denver Art Museum
Questions?
For questions about the registration, contact us at +1 800 709 1113 or email us at support@heslthtree.org
To ensure we can continue providing you with excellent venues, quality meals, and a valuable experience at our Roundtable meetings, we're introducing a modest registration fee. This helps us plan effectively and guarantees your spot at these important gatherings. If the fee is a financial burden, please reach out—we're happy to provide a promotional code to waive the cost. We appreciate your understanding and look forward to seeing you there.
- Evolving strategies in smoldering multiple myeloma (SMM)
- Personalizing care across precursor and newly diagnosed disease
- Overview of FDA-approved CAR-T therapies and how they are used today
- What’s changing in access, design, and earlier CAR T use
- The what, when, who, and how of bispecific antibodies
MRD Matters: Using Minimal Residual Disease to Guide Decisions, Tara Gregory, MD
OR
Staying Strong During Treatment: Managing Side Effects & Preventing Infection, Kate Mimken, RN, BSN, FNP-C
- Looking forward in myeloma care with new targets, new administrations, and new technologies
- CELMoDs, in vivo CAR T, antibody drug conjugates, and more
- Tara Gregory MD
- Jorge Monge, MD
- Peter Forsberg, MD
- Jeffrey V Matous, MD
- Kate Mimken, RN, BSN, FNP-C
Jenny Ahlstrom
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.
Tara K. Gregory, MD
Tara Gregory, MD, is a medical oncologist at the Colorado Blood Cancer Institute and Co-Director of the Plasma Cell Dyscrasia Program. She specializes in the treatment of multiple myeloma, amyloidosis, and other plasma cell disorders, with expertise in stem cell transplantation and cellular therapies. Dr. Gregory is actively involved in clinical research and has dedicated her career to advancing treatment options and improving outcomes for patients with blood cancers.
Jorge Monge, MD
Jorge Monge, MD, is a hematologist and medical oncologist at the University of Colorado specializing in multiple myeloma and other plasma cell disorders. He is actively involved in clinical research focused on advancing innovative therapies and improving outcomes for patients with blood cancers. Dr. Monge is committed to providing personalized, patient-centered care while helping bring the latest treatment advances to the myeloma community.
Peter A. Forsberg, MD
Peter A. Forsberg, MD, is a hematologist and medical oncologist at the Colorado Blood Cancer Institute specializing in multiple myeloma and other plasma cell disorders. He serves as Director of Translational Research and is actively involved in clinical trials focused on developing new treatment options for patients with blood cancers. Dr. Forsberg is dedicated to advancing innovative therapies while providing compassionate, patient-centered care.
Jeffrey V Matous, MD
Jeffrey V. Matous, MD, is a hematologist and medical oncologist at the Colorado Blood Cancer Institute with a special focus on multiple myeloma and other plasma cell disorders. He has been a leader in clinical research for more than two decades, helping bring innovative therapies and clinical trials to patients with blood cancers. Dr. Matous is dedicated to advancing myeloma care while providing personalized, patient-centered treatment.
Kate Mimken, RN, BSN, FNP-C
Kate Mimken, RN, BSN, MSN, FNP-C, is a nurse practitioner at the Colorado Blood Cancer Institute with extensive experience caring for patients with blood cancers. Throughout her oncology career, she has focused on helping patients navigate treatment, manage side effects, and maintain quality of life. Kate is passionate about patient education and empowering individuals and families with practical information to support their care journey.